Medicenna Therapeutics Corp. MDNA

Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference New clinical data for bizaxofusp, used for the treatment of unresectable recurrent IDH-WT glioblastoma, a uniformly fatal form of brain cancer, will also be presented during an oral session at an upcoming medical conference Enrolment in the Phase 1/2 ABILITY-1 study remains on track for completion in Q3 2026; Medicenna plans to explore with regulators on a potential expedited

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships Enrolment in the NEO-CYT Phase 1b trial, funded

New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 active granted patents and applicationsTORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today anno

Medicenna Therapeutics (MDNA.TO) said Wednesday that its lead compound MDNA11 was featured in a post

NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with locally advanced melanoma will be randomized in this Investigator-sponsored, multicenter Phase 1b NEO-CYT trial led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale” and sponsored by Fondazione Melanoma Onlus Together with the ongoing Phase 1/2 ABILITY-1 expansion

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit

Base shelf prospectus is accessible on SEDAR+NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that, in connection with its previously announced marketed public offering (the “Offering”) of unit

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized the terms of its previously-announced marketed underwritten public offering of securities of th

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today the launch of a marketed public offering (the “Offering”) of securities of the Company (the “Securities”). The type of Securities to be issued,

Medicenna Therapeutics (MDNA.TO) reported Tuesday that the first patient has been dosed in a Phase 1

NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2 ABILITY-1 study NEO-CYT is a Phase 1b randomized, multi-centre trial sponsored by Fondazione Melanoma Onlus and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale," Naples, Italy, evaluating MDNA11 in combination with nivolumab, with or without ipilimu

NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale”, a leading cancer centre in EuropeTORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer an

With Canadian retail sales showing a modest increase and central banks holding interest rates steady, the market is navigating through a period of cautious optimism. In such conditions, investors often look to smaller or newer companies for opportunities, and penny stocks—despite their old-fashioned name—can offer surprising value when paired with strong financial foundations. This article highlights three penny stocks that stand out for their financial strength, offering potential stability...

Medicenna Therapeutics (MDNA.TO), trading near 52 week lows, on Tuesday presented new "positive" pre

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human primate comparison against an anti-PD-1 x IL-2α-biased bispecific demonstrates MDNA113’s superior tolerability and significantly wider therapeutic window MDNA113 was well tolerated at doses up to 50 mg/kg in non-human primates with pharmacokinetics consistent with approved anti-PD-1 therapies, su

TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place in Toronto on April 21-22, 2026. D